This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Silver, R. Imatinib mesylate (GleevecTM) reduces phlebotomy requirements in polycythemia vera. Leukemia 17, 1186–1187 (2003). https://doi.org/10.1038/sj.leu.2402938
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402938
This article is cited by
-
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001
International Journal of Hematology (2009)
-
Phase II open label trial of imatinib in polycythemia rubra vera
International Journal of Hematology (2008)
-
Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate
Current Hematologic Malignancy Reports (2007)
-
Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia
Current Hematologic Malignancy Reports (2006)